Itamar Medical Funds Clinical Study to Evaluate Potential Impact of CPAP Therapy to Patients with COVID-19 - Seite 3

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding market opportunity and impact of COVID-19 on our business. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described elsewhere in our filings made with the Israel Securities Authority and with the Securities and Exchange Commission, including in the Company’s latest Annual Report on Form 20-F filed on April 3, 2020. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Itamar Medical disclaims any obligation to update these forward-looking statements.

The contents of any website of hyperlinks mentioned in this press release are for informational purposes only and the contents thereof are not part of this press release nor is it incorporated herein by reference.

Company Contact
Itamar Medical Ltd.
Shy Basson
Chief Financial Officer and U.S. Chief Operating Officer
Phone: [phone]
[e-mail]

Investor Relations Contact (U.S.)
Lazar FINN Partners
David Carey
Phone: [phone]
[e-mail]